R&D Day showcased remarkable Investigator optimism, continued strengthening supportive data, and significant progress with Phase 3 OVATION 3 Study in pursuit of first frontline immunotherapy for advan ...
Presented new subgroup analyses from phase 3 clinical trial of CAN-2409 in localized prostate cancer at the American Society ...
Long before automatic updates, the Windows 95 team tweaked third-party software to keep it running How to get that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback